159 related articles for article (PubMed ID: 18268938)
1. Gender differences in the association between C-reactive protein, lung function impairment, and COPD.
Olafsdóttir IS; Gíslason T; Thjódleifsson B; Olafsson I; Gíslason D; Jõgi R; Janson C
Int J Chron Obstruct Pulmon Dis; 2007; 2(4):635-42. PubMed ID: 18268938
[TBL] [Abstract][Full Text] [Related]
2. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland.
Thorleifsson SJ; Margretardottir OB; Gudmundsson G; Olafsson I; Benediktsdottir B; Janson C; Buist AS; Gislason T
Respir Med; 2009 Oct; 103(10):1548-53. PubMed ID: 19427181
[TBL] [Abstract][Full Text] [Related]
3. The prevalence of chronic airflow obstruction in three cities in the Nordic-Baltic region.
Broström E; Jõgi R; Gislason T; Benediktsdottir B; Burney PGJ; Janson C
Respir Med; 2018 Oct; 143():8-13. PubMed ID: 30261997
[TBL] [Abstract][Full Text] [Related]
4. Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study.
Margretardottir OB; Thorleifsson SJ; Gudmundsson G; Olafsson I; Benediktsdottir B; Janson C; Buist AS; Gislason T
COPD; 2009 Aug; 6(4):250-5. PubMed ID: 19811383
[TBL] [Abstract][Full Text] [Related]
5. Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS.
Garudadri S; Woodruff PG; Han MK; Curtis JL; Barr RG; Bleecker ER; Bowler RP; Comellas A; Cooper CB; Criner G; Dransfield MT; Hansel NN; Paine R; Krishnan JA; Peters SP; Hastie AT; Martinez FJ; O'Neal WK; Couper DJ; Alexis NE; Christenson SA
Chest; 2019 May; 155(5):908-917. PubMed ID: 30684474
[TBL] [Abstract][Full Text] [Related]
6. [Correlation among the levels of C-reactive protein and interleukin-18, quality of life, and lung function in patients with chronic obstructive pulmonary disease].
Long H; Luo H; Chen P; Li Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 36(11):1090-6. PubMed ID: 22169727
[TBL] [Abstract][Full Text] [Related]
7. Decline in FEV1 in relation to incident chronic obstructive pulmonary disease in a cohort with respiratory symptoms.
Lindberg A; Larsson LG; Rönmark E; Jonsson AC; Larsson K; Lundbäck B
COPD; 2007 Mar; 4(1):5-13. PubMed ID: 17364672
[TBL] [Abstract][Full Text] [Related]
8. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study.
Shaaban R; Kony S; Driss F; Leynaert B; Soussan D; Pin I; Neukirch F; Zureik M
Respir Med; 2006 Dec; 100(12):2112-20. PubMed ID: 16650972
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein levels in stable COPD patients: a case-control study.
Silva DR; Gazzana MB; Knorst MM
Int J Chron Obstruct Pulmon Dis; 2015; 10():1719-25. PubMed ID: 26357470
[TBL] [Abstract][Full Text] [Related]
11. Fixed ratio or lower limit of normal for the FEV
Wollmer P; Frantz S; Engström G; Dencker M; Löfdahl CG; Nihlén U
Clin Physiol Funct Imaging; 2017 May; 37(3):263-269. PubMed ID: 26443700
[TBL] [Abstract][Full Text] [Related]
12. [C-reactive protein level and the correlation between lung function and CRP levels in patients with chronic obstructive pulmonary diseases].
Wu SJ; Chen P; Jiang XN; Liu ZJ
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 30(4):444-6. PubMed ID: 16190395
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal association of C-reactive protein and lung function over 13 years: The EPIC-Norfolk study.
Ahmadi-Abhari S; Kaptoge S; Luben RN; Wareham NJ; Khaw KT
Am J Epidemiol; 2014 Jan; 179(1):48-56. PubMed ID: 24064740
[TBL] [Abstract][Full Text] [Related]
14. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromsø Study 2001.
Melbye H; Halvorsen DS; Hartz I; Medbø A; Brox J; Eggen AE; Njølstad I
Respir Med; 2007 Dec; 101(12):2541-9. PubMed ID: 17825547
[TBL] [Abstract][Full Text] [Related]
15. Systemic inflammation and decline in lung function in a general population: a prospective study.
Fogarty AW; Jones S; Britton JR; Lewis SA; McKeever TM
Thorax; 2007 Jun; 62(6):515-20. PubMed ID: 17251312
[TBL] [Abstract][Full Text] [Related]
16. Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease.
Whittaker HR; Pimenta JM; Jarvis D; Kiddle SJ; Quint JK
Int J Chron Obstruct Pulmon Dis; 2020; 15():3079-3091. PubMed ID: 33268984
[TBL] [Abstract][Full Text] [Related]
17. What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study.
Karrasch S; Brüske I; Smith MP; Thorand B; Huth C; Ladwig KH; Kronenberg F; Heinrich J; Holle R; Peters A; Schulz H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1881-94. PubMed ID: 27574413
[TBL] [Abstract][Full Text] [Related]
18. Gender difference in the association between smoking and lung function: exploring the role of C-reactive protein as a mediating factor.
Chen M; Li Y; Zhang D; Wu Y
Public Health; 2020 Jun; 183():88-93. PubMed ID: 32454325
[TBL] [Abstract][Full Text] [Related]
19. Airflow obstruction, atherosclerosis and cardiovascular risk factors in the AGES Reykjavik study.
Gudmundsson G; Margretardottir OB; Sigurdsson MI; Harris TB; Launer LJ; Sigurdsson S; Olafsson O; Aspelund T; Gudnason V
Atherosclerosis; 2016 Sep; 252():122-127. PubMed ID: 27522264
[TBL] [Abstract][Full Text] [Related]
20. Effects of active smoking on airway and systemic inflammation profiles in patients with chronic obstructive pulmonary disease.
Pelegrino NR; Tanni SE; Amaral RA; Angeleli AY; Correa C; Godoy I
Am J Med Sci; 2013 Jun; 345(6):440-5. PubMed ID: 22874622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
